financetom
Business
financetom
/
Business
/
Barclays sets new performance targets as 2024 pretax profit rises
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Barclays sets new performance targets as 2024 pretax profit rises
Feb 13, 2025 2:22 AM

LONDON (Reuters) - Barclays raised its 2025 performance targets on Thursday after reporting a better-than-expected 24% rise in annual pretax profit driven by investment banking income growth and strength in its domestic lending business.

The bank's shares - which had hit their highest levels since March 2011 on Wednesday - fell as much as 5.5% in early trading, which analysts said could be a bout of profit-taking linked to the lender's rising costs and UK impairments which both missed forecasts.

Barclays is the first major UK bank to report earnings for 2024, a year when Britain regained domestic political stability but lost the confidence of some international investors after the new Labour government brought in tax hikes it said were needed to fix the country's public finances.

CEO C.S. Venkatakrishnan last February laid out a three-year plan to revive the bank's share price, which included cutting costs, returning billions of pounds in excess capital to shareholders and investing in its higher-returning UK business.

The bank reported profit before tax for the year to December 31 of 8.1 billion pounds ($10.12 billion), slightly above the 8.07 billion pounds average of analysts' forecasts and higher than the 6.6 billion pounds it reported for the year prior.

Barclays said it met its performance targets for 2024, including a return on tangible equity of 10.5% in line with guidance for greater than 10%. Return on equity is a key measure of profitability.

"Our new guidance for 2025, including Group RoTE of around 11%, represents an important next step in the journey towards our 2026 targets, including Group RoTE of greater than 12%," Venkat said in a statement.

Analysts at Citi described the results as solid, but said there was not much new to excite shareholders either.

"...the strong run-up in the share price over the past year may temper any initial reaction, but the stock still appears inexpensive in our view," Citi said in a note to clients.

Barclays said it had extended the chairmanship of Nigel Higgins for another three years, as it looks to push ahead with its turnaround plan.

INVESTMENT BANK BOUNCE

Barclays' total income in its investment bank reached 11.8 billion pounds, just above analysts' forecasts for 11.6 billion pounds, as dealmaking and trading activity increased.

U.S. bank bosses have also expressed optimism for the year ahead, expecting that tax cuts and deregulation by President Donald Trump will energise businesses and capital markets as well as the economy.

Revenue from Barclays' traditional powerhouse trading business of fixed income, currencies and commodities (FICC) rose 29% to 934 million pounds in the final quarter of 2024, compared with an average of 29% among Wall Street's top 5 players, based on a Reuters calculation from earnings reports.

Barclays' equities revenue rose 40% to 604 million pounds over the same period, outpacing the average 29% gain at its U.S. rivals Bank of America, Citi, Goldman Sachs, JPMorgan and Morgan Stanley.

But for investment banking fees from M&A deals and fundraising, Barclays reported an 11% increase in income compared with a 35% average at its Wall Street rivals.

"Barclays is ... now beginning to deliver a reassuring level of consistency that it hadn't necessarily been known for in the past," RBC Brewin Dolphin investment manager Zoe Gillespie said, referring to the group as a whole.

($1 = 0.8004 pounds)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Novartis opens new plant in California to make cancer drugs
Novartis opens new plant in California to make cancer drugs
Nov 10, 2025
(Reuters) -Swiss drugmaker Novartis said on Monday it has opened a new 10,000-square-foot factory in Carlsbad, California, to make cancer treatments, as part of its pledge to invest billions into building U.S. sites. The plant will produce radioligand therapies, which are drugs that deliver cell-killing radioactive particles directly to tumors, the company said. Novartis already markets radioligand drugs Pluvicto for...
--Street Color: Novartis Expands Production Footprint With New Site in California
--Street Color: Novartis Expands Production Footprint With New Site in California
Nov 10, 2025
09:35 AM EST, 11/10/2025 (MT Newswires) -- Price: 127.00, Change: +0.64, Percent Change: +0.50 ...
Tyson Foods Sees A Turnaround Thanks To Its Multi-Protein Bet
Tyson Foods Sees A Turnaround Thanks To Its Multi-Protein Bet
Nov 10, 2025
Tyson Foods, Inc. ( TSN ) shares rose Monday following the release of its fourth-quarter and fiscal 2025 results, as the food giant delivered year-over-year gains in sales, adjusted operating income, and adjusted earnings per share, signaling progress in its turnaround efforts despite softer GAAP results. Tyson Foods ( TSN ) is a leading global protein company with well-known brands...
Lattice Semiconductor Insider Bought Shares Worth $1,892,115, According to a Recent SEC Filing
Lattice Semiconductor Insider Bought Shares Worth $1,892,115, According to a Recent SEC Filing
Nov 10, 2025
09:38 AM EST, 11/10/2025 (MT Newswires) -- Ford Tamer, Director, President and Chief Executive Officer, on November 06, 2025, executed a purchase for 30,000 shares in Lattice Semiconductor ( LSCC ) for $1,892,115. Following the Form 4 filing with the SEC, Tamer has control over a total of 285,745 common shares of the company, with 275,745 shares held directly and...
Copyright 2023-2026 - www.financetom.com All Rights Reserved